Tixagevimab plus Cilgavimab
Clinical Indication
Comments
Not recommended, within its marketing authorisation, for treating COVID‑19 as per NICE TA971.
Date of classification
July 2024
Do not prescribe
Drugs not recommended for use in LLR because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.